New eczema pill shows promise in Late-Stage trial
NCT ID NCT06277245
First seen Apr 29, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This study tested an experimental drug called LNK01001 in 356 adults with moderate to severe atopic dermatitis (eczema) that didn't improve enough with standard creams or other treatments. Participants received either the drug or a placebo pill for 16 weeks. The main goals were to see if the drug could clear skin and reduce itching more than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatological Hospital of Southern Medical University
Guangzhou, China
Conditions
Explore the condition pages connected to this study.